<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905709</url>
  </required_header>
  <id_info>
    <org_study_id>E-13-507</org_study_id>
    <nct_id>NCT01905709</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for C Diff Infection</brief_title>
  <official_title>Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Englewood Hospital and Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Englewood Hospital and Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide treatment with Fecal Microbiota Transplantation&#xD;
      (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI). It has&#xD;
      been shown that good bacteria (like that found in the stool from a healthy donor) attack&#xD;
      Clostridium difficile in multiple ways: they make substances that kill Clostridium difficile&#xD;
      - and they attach to the surface of the colon lining, which prevents the Clostridium&#xD;
      difficile toxin (poison) from attaching.&#xD;
&#xD;
      FMT involves infusing a mixture of saline and stool from a healthy donor into the bowel of&#xD;
      the patient with CDI during a colonoscopy.&#xD;
&#xD;
      The method used to deliver the FMT will depend on individual characteristics of the subject&#xD;
      and is at the discretion of the treating physician. FMT may be administered by the following&#xD;
      methods.&#xD;
&#xD;
        -  Colonoscopy: This method allows full endoscopic examination of the colon and exclusion&#xD;
           of comorbid conditions (such as IBD, malignancy or microscopic colitis) which may have&#xD;
           an impact on subject's treatment or response to therapy.&#xD;
&#xD;
        -  Sigmoidoscopy: This method still allows infusion of the stool into a more proximal&#xD;
           segment of the colon than an enema, but may not require sedation. This method may be&#xD;
           beneficial in subjects who are elderly or multiparous and who may have difficulty&#xD;
           retaining the material when given as enema. Sigmoidoscopic administration eliminates the&#xD;
           additional risks associated with colonoscopy in subjects who may not have a clear&#xD;
           indication for colonoscopy.&#xD;
&#xD;
        -  Retention enema: This method may be preferable in younger subjects who have already had&#xD;
           recent endoscopic evaluation, in subjects who prefer not to undergo endoscopy or in&#xD;
           subjects with significant co morbidities and may not tolerate endoscopy.&#xD;
&#xD;
      The physician will administer 300-500 mL of the fecal suspension in aliquots of 60 mL,&#xD;
      through the colonoscope or sigmoidoscope or 150 mL via retention enema. In cases of&#xD;
      colonoscopic delivery, the material will be delivered to the most proximal point of&#xD;
      insertion.&#xD;
&#xD;
      The subject is encouraged to retain stool for as long as possible.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CDI recurrence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of patients who did/did not experience relapse in the 8 weeks post FMT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150-500 ml of human fecal matter</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human fecal matter</intervention_name>
    <arm_group_label>All patients</arm_group_label>
    <other_name>human stool</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 years old.&#xD;
&#xD;
          2. Subject has recurrent or relapsing CDI defined as:&#xD;
&#xD;
               -  At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper&#xD;
                  with vancomycin with or without an alternative antibiotic (e.g., rifaximin,&#xD;
                  nitazoxanide, fidaxomicin). OR&#xD;
&#xD;
               -  At least two episodes of severe CDI resulting in hospitalization and associated&#xD;
                  with significant morbidity. OR&#xD;
&#xD;
               -  Moderate CDI not responding to standard therapy (vancomycin) for at least a week.&#xD;
                  OR&#xD;
&#xD;
               -  Severe C. difficile infection with toxic megacolon, not responding to standard&#xD;
                  therapy or the use of IVIg.&#xD;
&#xD;
          3. Subject is willing and able to provide informed consent.&#xD;
&#xD;
          4. If a female of childbearing potential, subject has agreed to use an acceptable form of&#xD;
             birth control for up to 4 weeks after FMT treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant.&#xD;
&#xD;
          2. Subject is unable to comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fiorillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Englewood Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Fiorillo, MD</last_name>
    <phone>201-945-6564</phone>
    <email>fiorillomd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosabel Cascina</last_name>
    <email>rosabel.cascina@ehmc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fiorillo, MD</last_name>
      <phone>201-945-6564</phone>
      <email>fiorillomd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dara Herman</last_name>
      <email>dara.herman@ehmchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Fiorillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mtichell Spinnell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Sapienza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandarsh Kancherla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Kaplounov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Meininger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.englewoodhealth.org/for-healthcare-professionals/clinical-research-center</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C diff</keyword>
  <keyword>CDI</keyword>
  <keyword>clostridium difficile associated diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

